Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N8FQ
|
|||
| Former ID |
DAP000720
|
|||
| Drug Name |
Reboxetine
|
|||
| Synonyms |
71620-89-8; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; Reboxetine [INN:BAN]; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; HSDB 7701; Edronax (TN); (R,R)-Reboxetine; AC1L2RJ0; SCHEMBL34533; CHEMBL383921; DTXSID1048257; MolPort-005-943-618; CHEBI:135342; ZINC3996032; BCP12060; AKOS015966368; DB00234; AN-34535; AK431803; AJ-47614
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Approved | [1], [2] | |
| Therapeutic Class |
Antidepressants
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H23NO3
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3
|
|||
| InChI |
1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
|
|||
| InChIKey |
CBQGYUDMJHNJBX-RTBURBONSA-N
|
|||
| CAS Number |
CAS 71620-89-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8189987, 11114256, 14776713, 14801082, 24723456, 43122598, 46504845, 50065436, 50168465, 57315782, 85177295, 85753305, 96026020, 104046804, 104334847, 126650576, 126683279, 134338008, 135253190, 135785545, 137001349, 142214143, 160698609, 160963582, 163213628, 177749680, 178101510, 179338235, 198950509, 198973023, 223519262, 223686602, 226420981, 241124852, 241169861, 246640544
|
|||
| ChEBI ID |
CHEBI:135342
|
|||
| ADReCS Drug ID | BADD_D01919 | |||
| SuperDrug ATC ID |
N06AX18
|
|||
| SuperDrug CAS ID |
cas=098769814
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Inhibitor | [3] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4808). | |||
| REF 2 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | |||
| REF 3 | Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.